These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
750 related articles for article (PubMed ID: 12932308)
1. Mild forms of von Willebrand disease: diagnosis and management. Federici AB Curr Hematol Rep; 2003 Sep; 2(5):373-80. PubMed ID: 12932308 [TBL] [Abstract][Full Text] [Related]
2. Von Willebrand's disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment. Castaman G; Federici AB; Rodeghiero F; Mannucci PM Haematologica; 2003 Jan; 88(1):94-108. PubMed ID: 12551832 [TBL] [Abstract][Full Text] [Related]
3. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio. Gadisseur A; Berneman Z; Schroyens W; Michiels JJ Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359 [TBL] [Abstract][Full Text] [Related]
4. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3. Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493 [TBL] [Abstract][Full Text] [Related]
5. The use of desmopressin in von Willebrand disease: the experience of the first 30 years (1977-2007). Federici AB Haemophilia; 2008 Jan; 14 Suppl 1():5-14. PubMed ID: 18173689 [TBL] [Abstract][Full Text] [Related]
6. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications. Michiels JJ; van de Velde A; van Vliet HH; van der Planken M; Schroyens W; Berneman Z Semin Thromb Hemost; 2002 Apr; 28(2):111-32. PubMed ID: 11992235 [TBL] [Abstract][Full Text] [Related]
7. Characterization, classification, and treatment of von Willebrand diseases: a critical appraisal of the literature and personal experiences. Michiels JJ; Gadisseur A; Budde U; Berneman Z; van der Planken M; Schroyens W; van de Velde A; van Vliet H Semin Thromb Hemost; 2005 Nov; 31(5):577-601. PubMed ID: 16276467 [TBL] [Abstract][Full Text] [Related]
8. Management of inherited von Willebrand disease in 2006. Federici AB Semin Thromb Hemost; 2006 Sep; 32(6):616-20. PubMed ID: 16977571 [TBL] [Abstract][Full Text] [Related]
11. Management of inherited von Willebrand disease in 2007. Federici AB; Mannucci PM Ann Med; 2007; 39(5):346-58. PubMed ID: 17701477 [TBL] [Abstract][Full Text] [Related]
12. Advances in the diagnosis and management of type 1 von Willebrand disease. Castaman G; Rodeghiero F Expert Rev Hematol; 2011 Feb; 4(1):95-106. PubMed ID: 21322782 [TBL] [Abstract][Full Text] [Related]
13. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease. Batlle J; López-Fernández MF; Fraga EL; Trillo AR; Pérez-Rodríguez MA Blood Coagul Fibrinolysis; 2009 Mar; 20(2):89-100. PubMed ID: 19786936 [TBL] [Abstract][Full Text] [Related]
14. Guidelines for the evaluation of intravenous desmopressin and von Willebrand factor/factor VIII concentrate in the treatment and prophylaxis of bleedings in von Willebrand disease types 1, 2, and 3. Michiels JJ; Gadisseur A; van der Planken M; Schroyens W; van de Velden A; Berneman Z Semin Thromb Hemost; 2006 Sep; 32(6):636-45. PubMed ID: 16977574 [TBL] [Abstract][Full Text] [Related]
15. Laboratory diagnosis and molecular basis of mild von Willebrand disease type 1. Michiels JJ; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van Vliet HH Acta Haematol; 2009; 121(2-3):85-97. PubMed ID: 19506353 [TBL] [Abstract][Full Text] [Related]
16. Recessive von Willebrand disease type 2 Normandy: variable expression of mild hemophilia and VWD type 1. Michiels JJ; Gadisseur A; Vangenegten I; Schroyens W; Berneman Z Acta Haematol; 2009; 121(2-3):119-27. PubMed ID: 19506358 [TBL] [Abstract][Full Text] [Related]
17. [Von Willebrand disease: characteristics and response to desmopressin. Study of 103 cases]. César JM; Avello AG; Vecino A; Cerveró C; Laraña JG; Fuertes IF; Villarrubia J; López J; de Oteyza JP; Velasco JL; Cantalapiedra A; Herrera P; Herrero S; Navarro JL Med Clin (Barc); 1998 Nov; 111(16):601-3. PubMed ID: 9881332 [TBL] [Abstract][Full Text] [Related]
18. Managing patients with von Willebrand disease type 1, 2 and 3 with desmopressin and von Willebrand factor-factor VIII concentrate in surgical settings. Michiels JJ; van Vliet HH; Berneman Z; Schroyens W; Gadisseur A Acta Haematol; 2009; 121(2-3):167-76. PubMed ID: 19506363 [TBL] [Abstract][Full Text] [Related]
19. PFA-100 monitoring of von Willebrand factor (VWF) responses to desmopressin (DDAVP) and factor VIII/VWF concentrate substitution in von Willebrand disease type 1 and 2. van Vliet HH; Kappers-Klunne MC; Leebeek FW; Michiels JJ Thromb Haemost; 2008 Sep; 100(3):462-8. PubMed ID: 18766263 [TBL] [Abstract][Full Text] [Related]
20. [Perioperative therapy of von Willebrand disease. Demonstration of pathophysiology, clinical problems and therapy options using two case reports]. Kleinschmidt S; Fuchs-Buder T; Wilhelm W; Seyfert UT; Mörsdorf S Anaesthesist; 2002 Oct; 51(10):825-34. PubMed ID: 12395174 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]